The Cooper Companies, Inc. COO
Composite 44/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 36/100 — a moderate mark against it.
Balance-sheet strength ranks 58/100 — a slight point in its favour.
Quality ranks 36/100 — a moderate mark against it. Valuation ranks 39/100 — a slight mark against it. Momentum ranks 42/100 — a slight mark against it.
What the company does The Cooper Companies operates two segments: CooperVision, which designs and sells contact lenses for vision challenges such as astigmatism and presbyopia, and CooperSurgical, which provides fertility products, contraception devices, and genomic services including genetic testing and cord blood storage.
Key financials Key financials show mixed profitability: ROE 2.9%, ROA 2.5%, ROCE 4.5%, gross margin 65.5%, operating margin -2.9%, and net margin 5.6%. Revenue growth is 5.1% while EPS growth is -4.2%. Debt/Equity is 0.33 with interest coverage of 5.17 and current ratio of 1.27.
Stock health SideraVIA scores indicate weak quality (37.3) and momentum (38.3), with valuation at 36.2. Piotroski F-Score is 6/9 and Altman Z is 3.45, suggesting moderate financial health. The stock is down -21.01% from its 52-week high, with RSI(14) at 38.10.
Price vs fair value The stock trades at a **discount of 14.90%** versus the analyst mean target of 81.50 (Barchart). - Analysts cite bullish sentiment on Cooper Companies stock (Barchart). - StockStory highlights the company as one to target this week, contrasting it with two facing headwinds.
Looking forward Forward P/E is 15.43 and PEG is 0.05, suggesting potential value if growth resumes. However, weak momentum and mixed profitability metrics warrant caution. The discount to the analyst target may reflect near-term headwinds or valuation sensitivity to operating margin recovery.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.